Pharmaceuticals

Protein Degradation Therapy Market Trends and Insights: Global Forecast to 2030

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the protein degradation therapy market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Protein Degradation Therapy Market from 2026 to 2030?

The protein degradation therapy market has experienced substantial growth in recent years. Its size is expected to increase from $1.25 billion in 2025 to $1.35 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.1%. This historical expansion is attributable to advancements in molecular biology research, the proliferation of targeted cancer therapies, a deeper understanding of protein dysfunction in diseases, successful early-stage clinical trials, and an uptick in venture capital funding for biotechnology.

The protein degradation therapy market size is anticipated to undergo significant expansion over the next few years, projected to reach $1.83 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This growth throughout the forecast period stems from a rising need for innovative cancer therapies, increased investments in precision oncology, the widening scope of protein degradation platforms, an escalation in clinical trial activities, and stronger regulatory support for advanced therapeutics. Noteworthy trends in the upcoming period encompass the heightened development of targeted protein degraders, an intensified focus on oncology applications, increased financial backing for PROTAC-based treatments, the enlargement of clinical pipeline candidates, and strengthened collaborations between pharmaceutical and biotechnology firms.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20603&type=smp

What Drivers Are Affecting Demand In The Protein Degradation Therapy Market?

An increasing prevalence of cancer is anticipated to drive expansion within the protein degradation therapy market in the coming years. Cancer encompasses a variety of illnesses characterized by the unchecked multiplication and spread of abnormal cells throughout the body. The incidence of cancer is increasing, largely attributable to several factors, among which the aging demographic plays a crucial role. Furthermore, lifestyle elements like smoking, inadequate nutrition, insufficient physical activity, and escalating obesity levels contribute to an elevated risk of diverse cancers. The necessity of protein degradation therapy for cancer treatment stems from its ability to specifically target and eradicate proteins essential for cancer proliferation and survival, potentially circumventing resistance encountered with conventional therapies. For example, a report released by the Switzerland-based intergovernmental World Health Organization in February 2024 projects more than 35 million new cancer cases by 2050, signifying a 77% surge from the approximately 20 million cases estimated in 2022. Additionally, high human development index (HDI) countries are expected to experience the most substantial rise in absolute figures, with an extra 4.8 million new cases forecasted for 2050 relative to 2022 projections. Consequently, the expanding prevalence of cancer is fueling the expansion of the protein degradation therapy market.

Which Segment Groups Are Influencing The Protein Degradation Therapy Market?

The protein degradation therapy market covered in this report is segmented –

1) By Type: Bavdegalutamide (ARV – 110), Vepdegestrant (ARV – 471)

2) By Application: Oncology, Neurodegenerative Diseases, Infectious Diseases, Other Applications

3) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Bavdegalutamide (ARV-110): Androgen Receptor Degraders, Prostate Cancer Therapy

2) By Vepdegestrant (ARV-471): Estrogen Receptor Degraders, Breast Cancer Therapy

What Industry Trends Are Transforming The Protein Degradation Therapy Market?

Leading companies in the protein degradation therapy market are adopting a strategic collaboration model to develop innovative treatments, utilize complementary specialized knowledge, share assets, and accelerate the discovery and progression of new drug candidates aimed at disease-causing proteins. These strategic partnerships involve organizations using each other’s strengths and resources to achieve mutual benefits and collective success. For instance, in February 2024, Arvinas, a U.S.-based biotechnology company, introduced its first oral PROTAC degrader (ARV-102), which is designed to cross the blood-brain barrier and target LRRK2 for neurodegenerative disease applications. The ARV-102 molecule possesses oral bioavailability, a brain-penetrant profile, and high specificity for LRRK2. This innovation strengthens companies’ product pipelines by addressing targets that were previously considered undruggable, although challenges persist regarding long-term safety, complexity in manufacturing, and optimizing pharmacokinetics given its larger molecular structure.

Who Are The Prominent Global Companies Shaping The Protein Degradation Therapy Market Landscape?

Major companies operating in the protein degradation therapy market are Relay Therapeutics, Arvinas Holding Company LLC, Kymera Therapeutics, Nurix Therapeutics, Vividion Therapeutics, Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics, Dialectic Therapeutics, Amphista Therapeutics, Biotheryx Inc., Cedilla Therapeutics, Dewpoint Therapeutics Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/protein-degradation-therapy-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Protein Degradation Therapy Market?

North America was the largest region in the protein degradation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Protein Degradation Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20603&type=smp

Browse Through More Reports Similar to the Global Protein Degradation Therapy Market 2026, By The Business Research Company

Home Infusion Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/home-infusion-therapy-global-market-report

Car T Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/car-t-therapy-global-market-report

Aromatherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/aromatherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795